See more : Namoi Cotton Limited (NAM.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Athira Pharma, Inc. (ATHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Athira Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fovea Jewelry Holdings, Ltd (FJHL) Income Statement Analysis – Financial Results
- Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866.SS) Income Statement Analysis – Financial Results
- Esken Limited (ESKN.L) Income Statement Analysis – Financial Results
- PT Sarana Menara Nusantara Tbk. (SMNUF) Income Statement Analysis – Financial Results
- Tri-Tech Holding Inc. (TRITF) Income Statement Analysis – Financial Results
Athira Pharma, Inc. (ATHA)
About Athira Pharma, Inc.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 969.00K | 1.05M | 479.00K | 2.00M | 0.00 | 0.00 |
| Gross Profit | -969.00K | -1.05M | -479.00K | -2.00M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 93.79M | 61.46M | 42.79M | 13.29M | 3.79M | 3.59M |
| General & Administrative | 33.30M | 32.55M | 21.23M | 6.71M | 1.66M | 1.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.30M | 32.55M | 21.23M | 6.71M | 1.66M | 1.42M |
| Other Expenses | -1.63M | -5.16M | -8.84M | -1.32M | -754.00K | -164.00K |
| Operating Expenses | 125.47M | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Cost & Expenses | 125.47M | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Interest Income | 7.64M | 3.22M | 337.00K | 124.00K | 51.00K | 85.00K |
| Interest Expense | 0.00 | 24.32M | 3.00K | 367.00K | 346.00K | 9.00K |
| Depreciation & Amortization | 969.00K | 1.05M | 479.00K | 2.00M | 2.00K | 5.01M |
| EBITDA | -116.70M | -94.59M | -54.37M | -19.01M | -4.82M | -79.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -125.47M | -104.02M | -64.02M | -20.00M | -5.45M | -5.01M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.79M | 8.38M | 9.17M | 40.00K | 288.00K | -88.00K |
| Income Before Tax | -117.67M | -95.64M | -54.85M | -19.96M | -5.16M | -5.10M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.38M | -479.00K | -1.32M | -459.00K | -76.00K |
| Net Income | -117.67M | -87.26M | -54.37M | -18.63M | -4.70M | -5.10M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.10 | -2.31 | -1.47 | -0.57 | -0.14 | -0.82 |
| EPS Diluted | -3.09 | -2.31 | -1.47 | -0.57 | -0.14 | -0.82 |
| Weighted Avg Shares Out | 38.02M | 37.73M | 36.92M | 32.49M | 32.62M | 6.19M |
| Weighted Avg Shares Out (Dil) | 38.02M | 37.73M | 36.92M | 32.49M | 32.62M | 6.19M |
ATHA Energy identifies high-grade uranium mineralization in new outcrops at Angilak
ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) said it has uncovered numerous outcrops hosting high-grade uranium mineralization at Angilak in Nunavut. The surficial mapping program, centered around the Lac 50 Deposit, identified mineralized outcrops between the Lac 48, Lac 50, Lac 52,...
ATHA Energy reveals updated technical report for Angilak uranium project
ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) has unveiled its updated 2024 technical report for its 100%-owned Angilak uranium project in Nunavut. The third-party updated technical report establishes a baseline Exploration Target for the Lac 50 Deposit of 60.8–98.2 million pounds of...
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients...
ATHA Energy appoints seasoned experts to leadership team
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has announced the appointment of Erinn Broshko as a non-executive director and Rhéal Assié as chief financial officer, starting November 6. The company said Broshko, a seasoned executive and lawyer, brings more than 25 years...
ATHA Energy and Terra Uranium enter into strategic option agreements on key uranium projects
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced that it has entered into option agreement with Terra Uranium Ltd (ASX:T92) which allow the two companies to earn significant interest in each other's uranium exploration projects. ATHA has granted Terra Uranium an option...
ATHA Energy Announces Option Agreements With Terra Uranium for Spire, Horizon, and Pasfield Projects
VANCOUVER, British Columbia, Oct. 11, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (CSE: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA”) is pleased to announce, in furtherance to its news release from August 20th, 2024 , the Company and Terra Uranium Ltd....
ATHA Energy CEO highlights 2024 growth priorities at TD Securities Nuclear Roundtable
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) CEO Troy Boisjoli highlighted the company's aggressive growth strategy and plans for the year ahead in a discussion at the TD Securities Annual Nuclear Fuel Cycle and Next Generation Nuclear Roundtable. ATHA, listed in April...
ATHA Energy secures entire Lac 50 structural corridor at Angilak uranium project
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has expanded its Angilak Project in Nunavut by acquiring the entire Lac 50 structural corridor, along with an additional prospective parallel corridor. Both corridors are linked to the Snowbird Tectonic Zone, a significant crustal structure...
Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring
Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025
Source: https://incomestatements.info
Category: Stock Reports